The present study proved with the mixed‐effects model for repeated measure approach that time courses of the decreases in GGT and ALT levels during the intervention to treat hyperglycaemia and obesity with the SGLT2 inhibitor, tofogliflozin, are distinct from each other. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.